Studies indicated higher rate of vitamin D deficiency in Iranian children and also its potential role in both pathogenesis and management of Type 1 diabetes mellitus (T1DM), so we aimed to evaluate the impact of vitamin D supplement therapy on glycemic control and level of Insulin-like growth factor-I (IGF-1) in children with T1DM.
In this cross-sectional study, a total of 30 children with T1DM and serum 25-hydroxyvitamin D levels lower than 29 ng/ml were enrolled. In addition to insulin therapy, the patients underwent treatment with 50,000 units of cholecalciferol (vitamin D3) once a week for a period of 12 weeks. Mean of serum vitamin D, IGF-1 and hemoglobin A1C (HbA1C), before and after treatment were compared.
Serum vitamin D increased significantly after 12 weeks treatment (P<0.001). Mean level of IGF-1 and HbA1c increased and decreased significantly after treatment with vitamin D supplement, respectively (P=0.01 and 0.04). There was a significant negative correlation between HbA1c and IGF-1 (r= -0.69, P<0.001) and 25(OH) D (r= -0.40, P=0.05), 12 weeks after treatment with Vitamin D3 supplement.
Our results indicated that vitamin D treatment enhance level IGF-1 which was accompanied by decreased levels of HbA1c in patients with T1DM. So, developing a proper vitamin D treatment guideline specified in T1DM patients would result in better glycemic control and proper prevention of its related microvascular and macrovascular complication.
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.